ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
NCT06224673
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are naturally produced by the body's immune system to help fight infections. ARX788 consists of antibodies that have been attached to a toxin that has the potential to kill cancer cells.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HER2 Low Breast Carcinoma
- Triple Negative Breast Cancer
- Hormone-receptor-positive Breast Cancer
- Hormone Receptor Positive Breast Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Laura Huppert, MD, BA
- Last updated on ClinicalTrials.gov
- June 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California, San Francisco · San Francisco, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.